Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone by since cell biologist Judith Campisi, PhD, paradoxically demonstrated that these same cells can promote cancer growth in a laboratory setting. Until now, it has not been clear whether this occurs inside the body.
Using advanced genetic reporters and spatial transcriptomics in mouse and human lung adenocarcinoma, researchers from UC San Francisco have identified senescent fibroblasts within the tumor microenvironment and found that they cluster near a highly aggressive, plastic subset of tumor cells that can change identity to resist treatment.
Through experiments using tumor organoids and adoptive transfer models, the research team discovered that these senescent fibroblasts secrete protein molecules such as APOE that reprogram tumor metabolism, fueling this plastic behavior. Strikingly, when the researchers used senolytic therapies to remove senescent fibroblasts, these highly adaptable cancer cells decreased dramatically, and aggressive tumors regressed in animal models.
Their study published November 3 in Cell Stem Cell.
“Lung cancer is so difficult to treat because tumor mutations keep evolving to develop drug resistance,” said senior author Tien Peng, MD, associate professor of pulmonary, critical care, allergy and sleep medicine. “What’s exciting about this work is that we identified a druggable cell population within the stroma that supports tumor.”
Using a drug-discovery approach to target senescent cells, the researchers were able to selectively clear senescent fibroblasts and, in doing so, reverse the metabolic and cellular changes that drive aggressive lung cancer.
Because senescent cells exhibit distinct drug sensitivities compared to cancer cells, targeting them may provide new therapeutic avenues to counteract tumor drug resistance.
“This work not only confirms the seminal observations of Judith Campisi two decades ago in living tissue but also uncovers a potential therapeutic opportunity: targeting senescent cells in the tumor niche to block cancer adaptation and growth, offering a new path toward translating basic aging biology into clinical oncology,” said Peng.
Additional Authors: Jin Young Lee, Nabora Reyes, Sang-Ho Woo, Nancy C. Allen, Tsukasa Kadota Andrew Lechner, Ritusree Biswas, Sakshi Goel, Fia Stratton, Chaoyuan Kuang, Tatsuya Tsukui, Vincent Auyeung, Aaron S. Mansfield, and Lindsay M. LaFave.
Funding: NIH grants R01HL160895 and R01HL155622 and CIRM DISC0-14460, the Tobacco-Related Disease Research Program postdoctoral award T33FT6395 and Basic Science Research Program through NRF of Korea (2020R1A6A3A03038781) and the Nina Ireland Program Award for human lung collection.
About UCSF Health: UCSF Health is recognized worldwide for its innovative patient care, reflecting the latest medical knowledge, advanced technologies and pioneering research. It includes the flagship UCSF Medical Center, which is a top-ranked specialty hospital, as well as UCSF Benioff Children’s Hospitals, with campuses in San Francisco and Oakland; two community hospitals, UCSF Health St. Mary's and UCSF Health Saint Francis; Langley Porter Psychiatric Hospital and Clinics; UCSF Benioff Children’s Physicians; and the UCSF Faculty Practice. These hospitals serve as the academic medical center of the University of California, San Francisco, which is world-renowned for its graduate-level health sciences education and biomedical research. UCSF Health has affiliations with hospitals and health organizations throughout the Bay Area. Visit http://www.ucsfhealth.org/. Follow UCSF Health on Facebook, Threads or LinkedIn.
